<?xml version = '1.0' encoding = 'UTF-8'?>
<?xml-stylesheet href="/rss/styledrssBMC.css" type="text/css"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns="http://purl.org/rss/1.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:extra="http://www.biomedcentral.com/xml/schemas/extra/" xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/" xmlns:cc="http://web.resource.org/cc/">
	<channel rdf:about="http://www.biomedcentral.com/rss">
		<extra:info rdf:parseType="Literal">
			<html:div xmlns:html="http://www.w3.org/1999/xhtml" style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif">
				<html:span style="font-weight:bold">This is an RSS newsfeed from BioMed Central</html:span>
				<html:br/>
				<html:span style="font-size: 12px;">It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit <html:br/><html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">http://www.biomedcentral.com/info/about/rss/</html:a><html:br/>
				</html:span>
			</html:div>
		</extra:info>
		<title>Journal of Negative Results in BioMedicine - Latest articles</title>
		<link>http://www.jnrbm.com</link>
		<description>The latest articles from Journal of Negative Results in BioMedicine (ISSN 1477-5751) published by 
				
				BioMed Central
		</description>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        <items>
            <rdf:Seq>
            
				    <rdf:li rdf:resource="http://www.jnrbm.com/content/7/1/3"/>			    
            
				    <rdf:li rdf:resource="http://www.jnrbm.com/content/7/1/2"/>			    
            
				    <rdf:li rdf:resource="http://www.jnrbm.com/content/7/1/1"/>			    
            
				    <rdf:li rdf:resource="http://www.jnrbm.com/content/6/1/11"/>			    
            
				    <rdf:li rdf:resource="http://www.jnrbm.com/content/6/1/10"/>			    
            
				    <rdf:li rdf:resource="http://www.jnrbm.com/content/6/1/9"/>			    
            
				    <rdf:li rdf:resource="http://www.jnrbm.com/content/6/1/8"/>			    
            
				    <rdf:li rdf:resource="http://www.jnrbm.com/content/6/1/7"/>			    
            
				    <rdf:li rdf:resource="http://www.jnrbm.com/content/6/1/6"/>			    
            
				    <rdf:li rdf:resource="http://www.jnrbm.com/content/6/1/5"/>			    
            
            </rdf:Seq>
        </items>
    </channel>  
    
		<item rdf:about="http://www.jnrbm.com/content/7/1/3">
            
            <title>Tolerance and rebound with zafirlukast in patients with persistent asthma</title>
			<description>Background:
The potential for tolerance to develop to zafirlukast, a cysteinyl leukotriene (CysLT) receptor antagonist (LRA) in persistent asthma, has not been specifically examined.ObjectiveTo look for any evidence of tolerance and potential for short-term clinical worsening on LRA withdrawal. Outcome measures included changes in; airway hyperresponsiveness to inhaled methacholine (PD20FEV1), daily symptoms and peak expiratory flows (PEF), sputum and blood cell profiles, sputum CysLT and prostaglandin (PG)E2 and exhaled nitric oxide (eNO) levels. 
Methods:
A double blind, placebo-controlled study of zafirlukast, 20 mg twice daily over 12 weeks in 21 asthmatics taking b2-agonists only (Group I), and 24 subjects treated with ICS (Group II). 
Results:
In Group I, zafirlukast significantly improved morning PEF and FEV1 compared to placebo (p&lt;0.01), and reduced morning waking with asthma from baseline after two weeks (p&lt;0.05). Similarly in Group II, FEV1 improved compared to placebo (p&lt;0.05), and there were early within-treatment group improvements in morning PEF, b2aagonist use and asthma severity scores (p&lt;0.05). However, most improvements with zafirlukast in Group I and to a lesser extent in Group II deteriorated toward baseline values over 12 weeks. In both groups, one week following zafirlukast withdrawal there were significant deteriorations in morning and evening PEFs and FEV1 compared with placebo (p&lt;0.05) and increased nocturnal awakenings in Group II (p&lt;0.05). There were no changes in PD20FEV1, sputum CysLT concentrations or exhaled nitric oxide (eNO) levels. However, blood neutrophils significantly increased in both groups following zafirlukast withdrawal compared to placebo (p=0.007). 
Conclusions:
Tolerance appears to develop to zafirlukast and there is rebound clinical deterioration on drug withdrawal, accompanied by a blood neutrophilia.</description>
			<link>http://www.jnrbm.com/content/7/1/3</link>
			
			 	<dc:creator>David W Reid, Neil L Misso, Shashi Aggarwal, Philip J Thompson, David P Johns and E. Haydn Walters</dc:creator>
			
			<dc:source>Journal of Negative Results in BioMedicine 2008, 7:3</dc:source>
			<dc:date>2008-05-19</dc:date>
			<dc:identifier>doi:10.1186/1477-5751-7-3</dc:identifier>
			
			
							
					<prism:publicationName>Journal of Negative Results in BioMedicine</prism:publicationName>
					
			
							
					<prism:issn>1477-5751</prism:issn>
					
			
							
					<prism:volume>7</prism:volume>
					
			
							
					<prism:startingPage>3</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-05-19</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.jnrbm.com/content/7/1/2">
            
            <title>Environmental enrichment has no effect on the development of dopaminergic and GABAergic fibers during methylphenidate treatment of early traumatized gerbils</title>
			<description>It is widely believed, that environmental factors play a crucial role in the etiology and outcome of psychiatric diseases such as Attention-Deficit/Hyperactivity Disorder (ADHD). A former study from our laboratory has shown that both methylphenidate (MP) and handling have a positive effect on the dopaminergic fiber density in the prefrontal cortex (PFC) of early traumatized gerbils (Meriones unguiculatus). The current study was performed to investigate if enriched environment during MP application has an additional influence on the dopaminergic and GABAergic fiber densities in the PFC and amygdala in this animal model. 
Animals received a single early dose of methamphetamine (MA; 50mg/kg; i.p.) on postnatal day (PD) 14, which is known to cause multiple changes in the subsequent development of several neurotransmitter systems including the dopaminergic systems, and were then treated with oral daily applications of MP (5mg/kg) from PD30-60. Animals treated this way were either transferred to an enriched environment after weaning (on PD30) or were kept under impoverished rearing conditions. 
There was no effect of an enriched environment on the dopaminergic or GABAergic fiber density neither in the PFC nor in the amygdala. With regard to former studies these results underline the particular impact of MP in the treatment of ADHD. </description>
			<link>http://www.jnrbm.com/content/7/1/2</link>
			
			 	<dc:creator>Susanne Brummelte, Thorsten Grund, Gunther H Moll, Gertraud Teuchert-Noodt and Ralph R Darwirs</dc:creator>
			
			<dc:source>Journal of Negative Results in BioMedicine 2008, 7:2</dc:source>
			<dc:date>2008-05-16</dc:date>
			<dc:identifier>doi:10.1186/1477-5751-7-2</dc:identifier>
			
			
							
					<prism:publicationName>Journal of Negative Results in BioMedicine</prism:publicationName>
					
			
							
					<prism:issn>1477-5751</prism:issn>
					
			
							
					<prism:volume>7</prism:volume>
					
			
							
					<prism:startingPage>2</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-05-16</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.jnrbm.com/content/7/1/1">
            
            <title>Body composition in male elite athletes, comparison of bioelectrical impedance spectroscopy with dual energy X-ray absorptiometry</title>
			<description>Background:
The aim of this study was to compare body composition results from bioelectrical spectroscopy (BIS) with results from dual energy X-ray absorptiometry (DXA) in a population of male elite athletes. Body composition was assessed using DXA (Lunar Prodigy, GE Lunar Corp., Madison, USA) and BIS (Hydra 4200, Xitron Technologies Inc, San Diego, California, USA) at the same occasion. Agreement between methods was assessed using paired t-tests and agreement-plots.
Results:
Thirty-three male elite athletes (soccer and ice hockey) were included in the study. The results showed that BIS underestimates the proportion of fat mass by 4.6% points in the ice hockey players. In soccer players the BIS resulted in a lower mean fat mass by 1.1% points. Agreement between the methods at the individual level was highly variable.
Conclusion:
Body composition results assessed by BIS in elite athletes should be interpreted with caution, especially in individual subjects. BIS may present values of fat mass that is either higher or lower than fat mass assessed by DXA, independent of true fat content of the individual.</description>
			<link>http://www.jnrbm.com/content/7/1/1</link>
			
			 	<dc:creator>Ulla Svantesson, Martina Zander, Sofia Klingberg and Frode Slinde</dc:creator>
			
			<dc:source>Journal of Negative Results in BioMedicine 2008, 7:1</dc:source>
			<dc:date>2008-01-22</dc:date>
			<dc:identifier>doi:10.1186/1477-5751-7-1</dc:identifier>
			
			
							
					<prism:publicationName>Journal of Negative Results in BioMedicine</prism:publicationName>
					
			
							
					<prism:issn>1477-5751</prism:issn>
					
			
							
					<prism:volume>7</prism:volume>
					
			
							
					<prism:startingPage>1</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-01-22</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.jnrbm.com/content/6/1/11">
            
            <title>Effectiveness of low-dose doxycycline (LDD) on clinical symptoms of Sj&#246;gren's Syndrome: a randomized, double-blind, placebo controlled cross-over study</title>
			<description>Background:
Matrix metalloproteinases (MMPs) are proteolytic enzymes that may contribute to tissue destruction in Sj&#246;gren's syndrome (SS). Low-dose doxycycline (LDD) inhibits MMPs. We evaluated the efficacy of LDD for the subjective symptoms in primary SS patients.This was a randomized, double blind, placebo controlled cross-over study. 22 patients were randomly assigned to receive either 20 mg LDD or matching placebo twice a day for 10 weeks. The first medication period was followed by 10-week washout period, after which the patient received either LDD or placebo, depending on the first drug received, followed by the second washout period. Stimulated saliva flow rates and pH were measured before and after one and ten weeks of each medication and after washout periods. VAS scale was used to assess the effect of LDD and placebo on following six subjective symptoms: xerostomia; xerophtalmia; difficulty of swallowing; myalgia; arthralgia; and fatigue. The effect was evaluated for each medication and washout period separately.
Results:
Overall, the effects of medications on subjective symptoms were minor. Wilcoxon test demonstrated increased fatigue with LDD during medication (p &lt; 0.05). The differences may, however, reflect normal fluctuation of symptoms in SS patients.
Conclusion:
LDD may not be useful in reducing the primary SS symptoms.</description>
			<link>http://www.jnrbm.com/content/6/1/11</link>
			
			 	<dc:creator>Hubertus Seitsalo, Raija K Niemel&#228;, Magdalena Marinescu-Gava, Tuija Vuotila, Leo Tj&#228;derhane and Tuula Salo</dc:creator>
			
			<dc:source>Journal of Negative Results in BioMedicine 2007, 6:11</dc:source>
			<dc:date>2007-12-31</dc:date>
			<dc:identifier>doi:10.1186/1477-5751-6-11</dc:identifier>
			
			
							
					<prism:publicationName>Journal of Negative Results in BioMedicine</prism:publicationName>
					
			
							
					<prism:issn>1477-5751</prism:issn>
					
			
							
					<prism:volume>6</prism:volume>
					
			
							
					<prism:startingPage>11</prism:startingPage>
					
			
							
					<prism:publicationDate>2007-12-31</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.jnrbm.com/content/6/1/10">
            
            <title>Absence of autoantibodies connected to autoimmune polyendocrine syndrome type I and II and Addison's disease in girls and women with Turner syndrome</title>
			<description>Background:
A disturbance in the immune system has been described in Turner syndrome (45,X), with an association to low levels of IgG and IgM and decreased levels of T- and B-lymphocytes. Also different autoimmune diseases have been connected to Turner syndrome (45,X), thyroiditis being the most common. Other autoimmune diseases seen are inflammatory bowel disease, insulin dependent diabetes mellitus, Addison's disease, rheumatoid arthritis, myasthenia gravis, vitiligo, alopecia, pernicious anaemia and hypoparathyroidism, but the association to Turner syndrome is not definite.Besides the typical features of Turner syndrome (short stature, failure to enter puberty spontaneously and infertility due to ovarian insufficiency) ear problems are common. Otitis media and a progressive sensorineural hearing disorder are commonly seen. In the normal population there are known inner ear disorders related to autoimmune diseases. The aim of this study was to investigate patients with Turner syndrome regarding autoantibodies connected to the autoimmune disorders; autoimmune polyendocrine syndrome type I and II and Addison's disease, to screen for overlapping profile of autoantibodies.Blood samples from 110 Turner patients (7&#8211;65 years) were investigated using in vitro transcription, translation and immunoprecipitation techniques regarding autoantibodies connected to autoimmune polyendocrine syndrome type I and II and Addison's disease (21-hydroxylase, 17&#945;-hydroxylase, side-chain cleavage enzyme, aromatic L-amino acid decarboxylase, tyrosine hydroxylase and tryptophan hydroxylase).
Results:
The autoantibodies investigated were not overrepresented among the Turner patients.
Conclusion:
The autoimmune disorders associated with Turner syndrome do not seem to be of the same origin as Addison's disease, the type I or II autoimmune polyendocrine syndrome.</description>
			<link>http://www.jnrbm.com/content/6/1/10</link>
			
			 	<dc:creator>Annika E Stenberg, Lisskulla Sylv&#233;n, H&#229;kan Hedstrand, Olle K&#228;mpe and Malou Hultcrantz</dc:creator>
			
			<dc:source>Journal of Negative Results in BioMedicine 2007, 6:10</dc:source>
			<dc:date>2007-12-18</dc:date>
			<dc:identifier>doi:10.1186/1477-5751-6-10</dc:identifier>
			
			
							
					<prism:publicationName>Journal of Negative Results in BioMedicine</prism:publicationName>
					
			
							
					<prism:issn>1477-5751</prism:issn>
					
			
							
					<prism:volume>6</prism:volume>
					
			
							
					<prism:startingPage>10</prism:startingPage>
					
			
							
					<prism:publicationDate>2007-12-18</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.jnrbm.com/content/6/1/9">
            
            <title>Functional polymorphisms in the promoter regions of MMP2 and MMP3 are not associated with melanoma progression</title>
			<description>Background:
The matrix metalloproteinases (MMPs) are enzymes that cleave various components of the extracellular matrix (ECM) and basement membranes. MMPs are expressed in melanocytes and their overexpression has been linked to tumor development, progression and metastasis. At the genetic level, the following functional promoter polymorphisms are known to modify the gene transcription: -1306 C/T and -735 C/T in the MMP2 gene, and -1171 5A/6A in the MMP3 gene. Functional polymorphisms in MMP genes' promoter regions may modulate the risk for melanoma progression.
Methods:
We evaluated MMP2 and MMP3 germline polymorphisms in a group of 1002 melanoma patients using PCR-based methods, including fragment size analysis and melting temperature profiles. Two-sided Chi-Square, Cochran-Armitage tests for trend, Fisher's exact tests, and Kendall's Tau tests were performed to evaluate the associations between genotype and various clinical and epidemiologic factors. Multivariate analyses were conducted using logistic regression, adjusting for known melanoma confounders such as age, sex, phenotypic index, moles, freckles, and race. Survival estimates were computed using the Kaplan-Meier method and differences in survival were assessed using the log rank test.
Results:
All genotypes were in Hardy-Weinberg equilibrium. After adjustment for age, sex and phenotypic characteristics of melanoma risk, no significant associations were identified with the clinical, pathological, and epidemiological variables studied. The melting profile for MMP2 -735 C/T identified a new change in one sample. A new PCR-amplification followed by direct sequencing confirmed a heterozygote G to A substitution at position -729.
Conclusion:
This study does not provide strong evidence for further investigation into the role of the MMP2 and MMP3 variants in melanoma progression.</description>
			<link>http://www.jnrbm.com/content/6/1/9</link>
			
			 	<dc:creator>Javier Cotignola, Pampa Roy, Ami Patel, Nicole Ishill, Shivang Shah, Alan Houghton, Daniel Coit, Allan Halpern, Klaus Busam, Marianne Berwick and Irene Orlow</dc:creator>
			
			<dc:source>Journal of Negative Results in BioMedicine 2007, 6:9</dc:source>
			<dc:date>2007-10-24</dc:date>
			<dc:identifier>doi:10.1186/1477-5751-6-9</dc:identifier>
			
			
							
					<prism:publicationName>Journal of Negative Results in BioMedicine</prism:publicationName>
					
			
							
					<prism:issn>1477-5751</prism:issn>
					
			
							
					<prism:volume>6</prism:volume>
					
			
							
					<prism:startingPage>9</prism:startingPage>
					
			
							
					<prism:publicationDate>2007-10-24</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.jnrbm.com/content/6/1/8">
            
            <title>Peripheral nervous system manifestations in a Sandhoff disease mouse model: nerve conduction, myelin structure, lipid analysis</title>
			<description>Background:
Sandhoff disease is an inherited lysosomal storage disease caused by a mutation in the gene for the &#946;-subunit (Hexb gene) of &#946;-hexosaminidase A (&#945;&#946;) and B (&#946;&#946;). The &#946;-subunit together with the GM2 activator protein catabolize ganglioside GM2. This enzyme deficiency results in GM2 accumulation primarily in the central nervous system. To investigate how abnormal GM2 catabolism affects the peripheral nervous system in a mouse model of Sandhoff disease (Hexb-/-), we examined the electrophysiology of dissected sciatic nerves, structure of central and peripheral myelin, and lipid composition of the peripheral nervous system.
Results:
We detected no significant difference in signal impulse conduction velocity or any consistent change in the frequency-dependent conduction slowing and failure between freshly dissected sciatic nerves from the Hexb+/- and Hexb-/- mice. The low-angle x-ray diffraction patterns from freshly dissected sciatic and optic nerves of Hexb+/- and Hexb-/- mice showed normal myelin periods; however, Hexb-/- mice displayed a ~10% decrease in the relative amount of compact optic nerve myelin, which is consistent with the previously established reduction in myelin-enriched lipids (cerebrosides and sulfatides) in brains of Hexb-/- mice. Finally, analysis of lipid composition revealed that GM2 content was present in the sciatic nerve of the Hexb-/- mice (undetectable in Hexb+/-).
Conclusion:
Our findings demonstrate the absence of significant functional, structural, or compositional abnormalities in the peripheral nervous system of the murine model for Sandhoff disease, but do show the potential value of integrating multiple techniques to evaluate myelin structure and function in nervous system disorders.</description>
			<link>http://www.jnrbm.com/content/6/1/8</link>
			
			 	<dc:creator>Melanie A McNally, Rena C Baek, Robin L Avila, Thomas N Seyfried, Gary R Strichartz and Daniel A Kirschner</dc:creator>
			
			<dc:source>Journal of Negative Results in BioMedicine 2007, 6:8</dc:source>
			<dc:date>2007-07-10</dc:date>
			<dc:identifier>doi:10.1186/1477-5751-6-8</dc:identifier>
			
			
							
					<prism:publicationName>Journal of Negative Results in BioMedicine</prism:publicationName>
					
			
							
					<prism:issn>1477-5751</prism:issn>
					
			
							
					<prism:volume>6</prism:volume>
					
			
							
					<prism:startingPage>8</prism:startingPage>
					
			
							
					<prism:publicationDate>2007-07-10</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.jnrbm.com/content/6/1/7">
            
            <title>Vitamin D and oestrogen receptor polymorphisms in developmental dysplasia of the hip and primary protrusio acetabuli &#8211; A preliminary study</title>
			<description>We investigated the association of developmental dysplasia of the hip (DDH) and primary protrusion acetabuli (PPA) with Vitamin D receptor polymorphisms Taq I and Fok I and oestrogen receptor polymorphisms Pvu II and Xba I. 45 patients with DDH and 20 patients with PPA were included in the study. Healthy controls (n = 101) aged 18&#8211;60 years were recruited from the same geographical area. The control subjects had a normal acetabular morphology based on a recent pelvic radiograph performed for an unrelated cause. DNA was obtained from all the subjects from peripheral blood. Genotype frequencies were compared in the three groups. The relationship between the genotype and morphology of the hip joint, severity of the disease, age at onset of disease and gender were examined. The oestrogen receptor Xba I wild-type genotype (XX, compared with Xx and xx combined) was more common in the DDH group (55.8%) than controls (37.9%), though this just failed to achieve statistical significance (p = 0.053, odds ratio = 2.1, 95% CI = 0.9&#8211;4.6). In the DDH group, homozygosity for the mutant Taq I Vitamin D receptor t allele was associated with higher acetabular index (Mann-Whitney U-test, p = 0.03). Pvu II pp oestrogen receptor genotype was associated with low centre edge angle (p = 0.07). This study suggests a possible correlation between gene polymorphism in the oestrogen and vitamin D receptors and susceptibility to, and severity of DDH. The Taq I vitamin D receptor polymorphisms may be associated with abnormal acetabular morphology leading to DDH while the Xba I oestrogen receptor XX genotype may be associated with increased risk of developing DDH. No such correlations were found in the group with PPA.</description>
			<link>http://www.jnrbm.com/content/6/1/7</link>
			
			 	<dc:creator>Birender Kapoor, Colin Dunlop, Charles Wynn-Jones, Anthony A Fryer, Richard C Strange and Nicola Maffulli</dc:creator>
			
			<dc:source>Journal of Negative Results in BioMedicine 2007, 6:7</dc:source>
			<dc:date>2007-06-28</dc:date>
			<dc:identifier>doi:10.1186/1477-5751-6-7</dc:identifier>
			
			
							
					<prism:publicationName>Journal of Negative Results in BioMedicine</prism:publicationName>
					
			
							
					<prism:issn>1477-5751</prism:issn>
					
			
							
					<prism:volume>6</prism:volume>
					
			
							
					<prism:startingPage>7</prism:startingPage>
					
			
							
					<prism:publicationDate>2007-06-28</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.jnrbm.com/content/6/1/6">
            
            <title>Variance in multiplex suspension array assays: carryover of microspheres between sample wells</title>
			<description>Background:
This study was undertaken because of the accidental observation that a sample of 60+ beads was obtained by the instrument from a completely dry, unused well in a 96 well plate. Others have observed unexplained outliers in replicated wells. The problem was first observed on an older instrument, and replicated on a new instrument.Methods and resultsData is presented from two instruments using a multiple blank following well experiment that shows a surprising amount of carryover that has an unexpected nature. When it occurs, it does not necessarily decline from one well to the next. There appears to be two types of carryover, one that is small, predictable and declines consistently, and another which is potentially very large, unpredictable, and does not decline. The former can be compensated for or ignored. The latter cannot be addressed without using multiple replicated samples or an intraplex method.
Conclusion:
This problem has significance for analysis of results obtained with suspended microarray instruments. A special notation is made that biostatisticians need to be made aware of these results before experiments are undertaken and data generated for them to analyze. The problem can be handled by enough replicated samples, or an intraplex method. The applicability of these results to oligonucleotide based assays is unknown.</description>
			<link>http://www.jnrbm.com/content/6/1/6</link>
			
			 	<dc:creator>Brian Hanley</dc:creator>
			
			<dc:source>Journal of Negative Results in BioMedicine 2007, 6:6</dc:source>
			<dc:date>2007-04-25</dc:date>
			<dc:identifier>doi:10.1186/1477-5751-6-6</dc:identifier>
			
			
							
					<prism:publicationName>Journal of Negative Results in BioMedicine</prism:publicationName>
					
			
							
					<prism:issn>1477-5751</prism:issn>
					
			
							
					<prism:volume>6</prism:volume>
					
			
							
					<prism:startingPage>6</prism:startingPage>
					
			
							
					<prism:publicationDate>2007-04-25</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.jnrbm.com/content/6/1/5">
            
            <title>Human pluripotent embryonal carcinoma NTERA2 cl.D1 cells maintain their typical morphology in an angiomyogenic medium</title>
			<description>Background:
Pluripotent embryonal carcinomas are good potential models, to study, "in vitro," the mechanisms that control differentiation during embryogenesis. The NTERA2cl.D1 (NT2/D1) cell line is a well known system of ectodermal differentiation. Retinoic acid (RA) induces a dorsal pattern of differentiation (essentially neurons) and bone morphogenetic protein (BMP) or hexamethylenebisacetamide (HMBA) induces a more ventral (epidermal) pattern of differentiation. However, whether these human cells could give rise to mesoderm derivatives as their counterpart in mouse remained elusive. We analyzed the morphological characteristics and transcriptional activation of genes pertinent in cardiac muscle and endothelium differentiation, during the growth of NT2/D1 cells in an inductive angiomyogenic medium with or without Bone Morphogenetic Protein 2 (BMP2).
Results:
Our experiments showed that NT2/D1 maintains their typical actin organization in angiomyogenic medium. Although the beta myosin heavy chain gene was never detected, all the other 15 genes analyzed maintained their expression throughout the time course of the experiment. Among them were early and late cardiac, endothelial, neuronal and teratocarcinoma genes.
Conclusion:
Our results suggest that despite the NT2/D1 cells natural tendency to differentiate into neuroectodermal lineages, they can activate genes of mesodermal lineages. Therefore, we believe that these pluripotent cells might still be a good model to study biological development of mesodermal derivatives, provided the right culture conditions are met.</description>
			<link>http://www.jnrbm.com/content/6/1/5</link>
			
			 	<dc:creator>Pedro D Sim&#245;es and Teresa Ramos</dc:creator>
			
			<dc:source>Journal of Negative Results in BioMedicine 2007, 6:5</dc:source>
			<dc:date>2007-04-18</dc:date>
			<dc:identifier>doi:10.1186/1477-5751-6-5</dc:identifier>
			
			
							
					<prism:publicationName>Journal of Negative Results in BioMedicine</prism:publicationName>
					
			
							
					<prism:issn>1477-5751</prism:issn>
					
			
							
					<prism:volume>6</prism:volume>
					
			
							
					<prism:startingPage>5</prism:startingPage>
					
			
							
					<prism:publicationDate>2007-04-18</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
		
    <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
         <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction"/>
         <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution"/>
         <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks"/>
	</cc:License>
</rdf:RDF>
